|
|
|
|
|
|
|
|
|
16.01.26 - 20:48
|
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire EN)
|
|
|
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering ("Offering") of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including July 16, 2026 (when the warrants expire) resulting in additional gross proceeds of up to approximately $10.56 million....
|
|
|
|
|
16.01.26 - 13:03
|
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million (GlobeNewswire EN)
|
|
|
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best efforts registered direct offering ("Offering") of 6,400,000 ordinary shares at an Offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The total gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, are expected to be $8.0 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including July 16, 2026 (when the warrants expire) resulting in additional gross proceeds of up to approximately $9.6 million. The Offering is expected to close on January 16, ...
|
|
|
13.01.26 - 14:03
|
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines (Business Wire)
|
|
|
NEW YORK & BOSTON--(BUSINESS WIRE)--#AI--Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA's venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors.
As part of the financing, the company has rebranded from VantAI to Proxima to reflect its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics. These next generation medicines work by controlling how proteins interact with one another, rather than simply inhibiting or activating a single target, and represent a superset that includes modalities such as molecular glues and PROTACs that have the potential to unlock historically undruggable disease targets.
The ...
|
|
|
13.01.26 - 05:00
|
Research: M Stanley's Latest HK Stock Focus List (Table) (AAStocks)
|
|
|
Stock | Potential Upside to Target PriceAlibaba (BABA.US) | 16.5%YANGTZE POWER (600900.SH) | 27.6%CONTEMPORARY AMPEREX (300750.SZ) | 32.7%DUALITYBIO-B (09606.HK) | 39.3%ESPRESSIF (688018.SH) | 26.9%HKEX (00388.HK) | 19.5%HKT-SS (06823.HK) | 10.7%NARI (600406.SH) | 12.3%PING AN (02318.HK) | 26.8%INOVANCE TECH (300124.SZ) | 22.5%S......
|
|
|
09.01.26 - 13:03
|
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco (GlobeNewswire EN)
|
|
|
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week....
|
|
|
09.01.26 - 06:15
|
HKEX Launches 6 New Stock Option Classes (AAStocks)
|
|
|
HKEX (00388.HK) has announced the launch of six new stock option classes effective on Monday, January 19, 2026, building on the strong momentum in the single stock options market and offering more choices to investors.These stocks include ZIJIN GOLD INTL (02259.HK), WUXI APPTEC (02359.HK), BEONE MEDICINES (06160.HK), LAOPU GOLD ......
|
|
|
08.01.26 - 09:15
|
Full-day Takeaway: HSI Down 309 pts; HSTI Down 60 pts; MEITUAN Down over 3%; CK ASSET, CKI HOLDINGS, CLP HOLDINGS, CIMC ENRIC, SHINEWAY PHARM Hit New Highs; Market Turnover Rises (AAStocks)
|
|
|
At close, HSI dropped 309 pts or 1.2% to 26,149. HSTI dropped 60 pts or 1.0% to 5,678. HSCEI fell 99 pts or 1.1% to 9,039. Market turnover reached $268.27 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $101, down 3.3%BABA (09988.HK) closed at $142.6, down 2.3%TENCENT (00700.HK) closed at $616, down 1.4%PING AN (02318.H......
|
|
|
08.01.26 - 05:30
|
Midday Takeaway: HSI Down 322 pts; HSTI Down 64 pts; LENOVO GROUP Down over 5%; CK ASSET, CKI HOLDINGS, CLP HOLDINGS, SHINEWAY PHARM, BOC AVIATION Hit New Highs (AAStocks)
|
|
|
At midday close, HSI dropped 322 pts or 1.2% to 26,136. HSTI dropped 64 pts or 1.1% to 5,673. HSCEI fell 103 pts or 1.1% to 9,034.Active Heavyweights:MEITUAN (03690.HK) closed at $101.6, down 2.8%XIAOMI (01810.HK) closed at $37.48, down 1.8%TENCENT (00700.HK) closed at $614, down 1.7%BABA (09988.HK) closed at $143.7, down 1.5%PI......
|
|
|
|
|
|
|
|
|
05.01.26 - 04:06
|
The ′biology winter′ thaws: why investors are piling into Hong Kong′s biotech IPOs (SCMP)
|
|
|
Hong Kong's biotech fundraising momentum is expect to extend into 2026, as licensing deals and strong post-initial public offering (IPO) trading last year persuaded investors that China's drug developers are worth backing again – even before they generate revenue.
“Chinese innovation drugs expanding into overseas markets have become the industry mainstream, indicating the domestic innovation sector has entered its harvest phase,” said Felix Huang, head of equity at Oakwise Capital. “New trends......
|
|
|
|
|
|
|
29.12.25 - 14:03
|
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA (GlobeNewswire EN)
|
|
|
BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the submission of its seventh annual Development Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). This DSUR (September 21, 2024, to September 2, 2025), reports no drug-related serious adverse events after a cumulative exposure of 37.4 patient-years, highlighting the safety and tolerability data profile of intranasal foralumab in treating neuroinflammatory diseases, including non-active secondary progressive multiple sclerosis (naSPMS), multiple system atrophy and Alzheimer's Disease (AD)....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
